Study tracks early adoption of liver histotripsy treatment

Дата публикации: 28-08-2026 19:00:01

It has been nearly three years since the U.S. Food and Drug Administration (FDA) cleared the HistoSonics Edison histotripsy system to treat primary and metastatic liver tumors. To examine how the technology's adoption and use have progressed, a research team at the University of Virginia, led by Allan Tsung, M.D., professor and chair of the Department of Surgery, sought to provide an early national snapshot of its use for this indication.

Основное содержимое страницы с новостью.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	FDA OKs Lyrfigtu for previously treated bile duct cancer	0	11.23	23-09-2026
2	Promising new option for skin cancer reconstruction uses hydrogel-based template	0	10.36	14-09-2026
3	New AI tool can predict where glioblastoma is most likely to return after initial surgery	0	5.59	28-09-2026
4	В НМИЦ радиологии впервые выполнили рансплантацию печени онкопациенту	0	7.69	01-10-2026
5	Jemperli (dostarlimab) accepted for priority review by the US FDA for dMMR/MSI-H locally advanced rectal cancer	0	9.74	24-08-2026
6	From professor to patient: One man's journey on the frontier of lung cancer treatment	0	7.28	27-09-2026
7	From professor to patient: One man's journey on the frontier of lung cancer treatment	0	7.28	27-09-2026
8	Large Tumor Surgery Approach Question	0	9.54	29-09-2026
9	Errors in Results, Figure 3, and Supplement 1	0	17.4	24-09-2026

Классификация: Наука. Схожих патентов: 0. Схожих новостей: 9. Тональность: 0. Информативность: 5.96. Источник: medicalxpress.com.